Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Jul 19;11(1):14674.
doi: 10.1038/s41598-021-94220-6.

Frequency and phenotype of headache in covid-19: a study of 2194 patients

Affiliations
Observational Study

Frequency and phenotype of headache in covid-19: a study of 2194 patients

David García-Azorín et al. Sci Rep. .

Abstract

To estimate the frequency of headache in patients with confirmed COVID-19 and characterize the phenotype of headache attributed to COVID-19, comparing patients depending on the need of hospitalization and sex, an observational study was done. We systematically screened all eligible patients from a reference population of 261,431 between March 8 (first case) and April 11, 2020. A physician administered a survey assessing demographic and clinical data and the phenotype of the headache. During the study period, 2194 patients out of the population at risk were diagnosed with COVID-19. Headache was described by 514/2194 patients (23.4%, 95% CI 21.7-25.3%), including 383/1614 (23.7%) outpatients and 131/580 (22.6%) inpatients. The headache phenotype was studied in detail in 458 patients (mean age, 51 years; 72% female; prior history of headache, 49%). Headache was the most frequent first symptom of COVID-19. Median headache onset was within 24 h, median duration was 7 days and persisted after 1 month in 13% of patients. Pain was bilateral (80%), predominantly frontal (71%), with pressing quality (75%), of severe intensity. Systemic symptoms were present in 98% of patients. Headache frequency and phenotype was similar in patients with and without need for hospitalization and when comparing male and female patients, being more intense in females.Trial registration: This study was supported by the Institute of Health Carlos III (ISCIII), code 07.04.467804.74011 and Regional Health Administration, Gerencia Regional de Salud, Castilla y Leon (GRS: 2289/A/2020).

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Flow diagram. Number of patients that were identified, screened, included, and excluded, with the specific reasons for non-participation.
Figure 2
Figure 2
Frequency of headache in the entire sample and in the groups of patients managed in primary care and hospital care settings. ITT Intention-to-treat. PP Per protocol.

References

    1. Mao L, et al. Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–690. doi: 10.1001/jamaneurol.2020.1127. - DOI - PMC - PubMed
    1. Trigo J, et al. Factors associated with the presence of headache in hospitalized COVID-19 patients and impact on prognosis: a retrospective cohort study. J. Headache Pain. 2020;21(1):94. doi: 10.1186/s10194-020-01165-8. - DOI - PMC - PubMed
    1. Poncet-Megemont L, et al. High prevalence of headaches during Covid-19 infection: a retrospective cohort study. Headache. 2020;60(10):2578–2582. doi: 10.1111/head.13923. - DOI - PMC - PubMed
    1. Lechien JR, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J. Int. Med. 2020;288(3):335–344. doi: 10.1111/joim.13089. - DOI - PMC - PubMed
    1. Guan W, et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382(18):1708–1720. doi: 10.1056/NEJMoa2002032. - DOI - PMC - PubMed

Publication types